Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
5 Top Stocks Cathie Wood Bought This Week
05:02pm, Friday, 05'th Aug 2022
Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
04:32am, Friday, 05'th Aug 2022 Benzinga
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
For A
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
04:30pm, Thursday, 04'th Aug 2022 Zacks Investment Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
Can Pacific Biosciences (PACB) Climb 261% to Reach the Level Wall Street Analysts Expect?
01:55pm, Thursday, 04'th Aug 2022 Zacks Investment Research
The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Pacific Biosciences of California (PACB) Q2 2022 Earnings Call Transcript
08:00am, Thursday, 04'th Aug 2022 The Motley Fool
PACB earnings call for the period ending June 30, 2022.
Pacific Biosciences of California, Inc's (PACB) CEO Christian Henry on Q2 2022 Results - Earnings Call Transcript
12:08am, Thursday, 04'th Aug 2022
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Todd Friedman – Director of Investor Relations Christian Henry
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
09:45pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
S&P 500 Leads Dramatic Turnaround For Global Markets, But Risks Remain Elevated
04:20pm, Tuesday, 02'nd Aug 2022 Investing.com
Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?
06:26am, Monday, 01'st Aug 2022 Zacks Investment Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
02:40am, Wednesday, 27'th Jul 2022
Pacific Biosciences of California "PacBio" is a prime candidate for the "Bio Boom" Portfolio in my Compounding Healthcare Seeking Alpha Marketplace Service. I discuss how PACB meets the criteria. PacB
PacBio Grants Equity Incentive Award to New Employee
12:00am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee
Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
04:01pm, Monday, 16'th May 2022 Benzinga
Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00.
Shares of Pacific Biosciences are trading down 2.74% over
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
11:00pm, Sunday, 08'th May 2022 GlobeNewswire Inc.
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing Advanced Automation Aims to Optimize Service Lab Efficiency and Highl
パックバイオ (PacBio)、iLACおよびロボティック･バイオロジー･インスティテュート株式会社 (Robotic Biology Institute) と共同で自動化ワークフローを開発
11:00pm, Sunday, 08'th May 2022 GlobeNewswire Inc.
先進的な自動化技術で、サービスラボの効率化とHiFiロングリードシーケンシングによる再現性の高いデータ出力の最適化を目指す 先進的な自動化技
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
02:54pm, Thursday, 05'th May 2022 Zacks Investment Research
PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.
